Skip to content

EBITDA at other companies

SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
-$8.11M
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.67M+30.9%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Incyte logo
IncyteINCY
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.74B+95.0%
Enterprise value$1.96B+84.0%
P/S-12.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Calculated from Syndax Pharmaceuticals’s reported figures.

$34.2Mebit+
$4.0MDepreciation Depletion & Amortization
=-$30.2M

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's EBITDA?
Syndax Pharmaceuticals (SNDX) reported EBITDA of -$30.2M in Q1 2026.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.